Thomas Shrader
Stock Analyst at BTIG
(1.65)
# 3,342
Out of 4,966 analysts
50
Total ratings
37.21%
Success rate
-1.53%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Buy | $59 → $60 | $15.52 | +286.60% | 3 | Aug 19, 2025 | |
| HROW Harrow | Maintains: Buy | $62 → $63 | $38.99 | +61.58% | 1 | Aug 14, 2025 | |
| VRNA Verona Pharma | Downgrades: Neutral | n/a | $105.91 | - | 4 | Jul 10, 2025 | |
| INMB INmune Bio | Downgrades: Neutral | n/a | $2.09 | - | 3 | Jul 1, 2025 | |
| ALDX Aldeyra Therapeutics | Maintains: Buy | $11 → $9 | $5.86 | +53.58% | 1 | Apr 7, 2025 | |
| OVID Ovid Therapeutics | Maintains: Buy | $5 → $4 | $1.25 | +220.00% | 3 | Mar 24, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $30.77 | +419.99% | 4 | Feb 24, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Buy | $41 | $17.30 | +136.99% | 1 | Jan 28, 2025 | |
| ALEC Alector | Maintains: Buy | $16 → $5 | $2.39 | +109.21% | 2 | Nov 26, 2024 | |
| ATHA Athira Pharma | Downgrades: Neutral | n/a | $0.39 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.08 | +284.62% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.53 | +1,422.36% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $5.00 | +1,100.00% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $2.12 | +230.19% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $6.65 | +125.56% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.42 | +2,995.24% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $10 | $1.88 | +431.91% | 2 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $1.31 | +1,579.39% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.62 | +3,057.89% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $2.92 | +447.95% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.40 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.65 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $9.42 | +515.71% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.43 | +109.79% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $132.65 | +160.84% | 3 | Feb 21, 2019 |
Biohaven
Aug 19, 2025
Maintains: Buy
Price Target: $59 → $60
Current: $15.52
Upside: +286.60%
Harrow
Aug 14, 2025
Maintains: Buy
Price Target: $62 → $63
Current: $38.99
Upside: +61.58%
Verona Pharma
Jul 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $105.91
Upside: -
INmune Bio
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.09
Upside: -
Aldeyra Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.86
Upside: +53.58%
Ovid Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.25
Upside: +220.00%
Vaxcyte
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $30.77
Upside: +419.99%
Arcturus Therapeutics Holdings
Jan 28, 2025
Initiates: Buy
Price Target: $41
Current: $17.30
Upside: +136.99%
Alector
Nov 26, 2024
Maintains: Buy
Price Target: $16 → $5
Current: $2.39
Upside: +109.21%
Athira Pharma
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
May 31, 2024
Initiates: Buy
Price Target: $8
Current: $2.08
Upside: +284.62%
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.53
Upside: +1,422.36%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $5.00
Upside: +1,100.00%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.12
Upside: +230.19%
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $6.65
Upside: +125.56%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.42
Upside: +2,995.24%
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $1.88
Upside: +431.91%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $1.31
Upside: +1,579.39%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.62
Upside: +3,057.89%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $2.92
Upside: +447.95%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.40
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $15.65
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $9.42
Upside: +515.71%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.43
Upside: +109.79%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $132.65
Upside: +160.84%